SCHEMBL336528

SCHEMBL336528

CC(C)(C)[Si](C)(C)OCCC(C=O)CCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DUT P33316 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10148383 0.93 TSHR (0.33) DUT
SCHEMBL16928562 0.91 TSHR (0.42) DUT
SCHEMBL9425765 0.89 DUT (0.37) DUT
SCHEMBL10181980 0.84
SCHEMBL1804485 0.82 DUT (0.32) DUT
SCHEMBL5847954 0.81 DUT (0.33) DUT
SCHEMBL5536879 0.81 DUT (0.34) DUT
SCHEMBL5528968 0.81 DUT (0.34) DUT
SCHEMBL8151339 0.80 TSHR (0.44) DUT
SCHEMBL29864586 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 EP disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 US disclosed
CN-113149983-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2024-03-29 CN disclosed
US-20230151012-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2023-05-18 US disclosed
EP-4112618-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2023-01-04 EP disclosed
EP-3912979-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2021-11-24 EP disclosed
CN-113149983-A Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2021-07-23 CN disclosed
US-20210171526-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-06-10 US disclosed
CN-106459049-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2020-11-27 CN disclosed
US-20180162861-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-06-14 US disclosed
US-9688676-B2 Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2017-06-27 US disclosed
US-20170129890-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2017-05-11 US disclosed
WO-2016196840-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-08 WO disclosed
US-20140106367-A1 SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS NORTH CAROLINA STATE UNIVERSITY (US) 2014-04-17 US disclosed
US-8530459-B2 Swallowtail motifs for imparting water solubility to porphyrinic compounds NORTH CAROLINA STATE UNIVERSITY (US) 2013-09-10 US disclosed
US-20120082621-A1 SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-04-05 US disclosed
US-8097609-B2 Swallowtail motifs for imparting water solubility to porphyrinic compounds NORTH CAROLINA STATE UNIVERSITY (US) 2012-01-17 US disclosed
US-8097609-B2 Swallowtail motifs for imparting water solubility to porphyrinic compounds NORTH CAROLINA STATE UNIVERSITY (US) 2012-01-17 US disclosed
US-20090297456-A1 SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-12-03 US disclosed
US-20090297456-A1 SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171526-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK DUT 1844/4885
US-20180162861-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK DUT 1844/4885
US-20170129890-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK DUT 1844/4885
US-20120082621-A1 SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS ALK, ACVRL1, ACVR1 DUT 4734/4885
US-20090297456-A1 SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS ALK, ACVRL1, ACVR1 DUT 4732/4885
US-20230151012-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK DUT 1844/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK DUT 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.